Tarsus Pharmaceuticals, Inc. (TARS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TARS currently has 43M outstanding shares. with limited dilution risk as only 6.22M additional shares (14.5%) are authorized for issuance. The company has diluted shareholders by 15.17% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 06, 2026 |
10-Q filing | 43.0M shares outstanding |
43M | 6.2M |
| Nov 04, 2025 |
10-Q filing | 42.6M shares outstanding |
43M | 6.2M |
| Aug 06, 2025 |
10-Q filing | 42.4M shares outstanding |
42M | 6.2M |
| May 01, 2025 |
10-Q filing | 39.3M shares outstanding |
39M | 6.2M |
| Mar 18, 2025 |
8-K filing: Tarsus Pharmaceuticals, Inc. completed the sale and issuance of 3,230,336 shares of common stock at $44.50 per share, including the exercise in full of the Underwriters' option, receiving net proceeds of approximately $134.8 million. ($134.8M proceeds) |
38M | 6.2M |
| Feb 25, 2025 |
10-K filing | 37.6M shares outstanding |
38M | 6.2M |
| Nov 13, 2024 |
10-Q filing | 38.4M shares outstanding |
38M | 6.2M |
| Aug 08, 2024 |
10-Q filing | 37.8M shares outstanding |
38M | 6.2M |
| May 08, 2024 |
10-Q filing | 35.3M shares outstanding |
35M | 6.2M |
| Mar 05, 2024 |
8-K filing: Tarsus Pharmaceuticals, Inc. completed the sale and issuance of 3,281,250 shares of common stock and pre-funded warrants to purchase 312,500 shares of common stock for net proceeds of approximately $107.8 million. ($107.8M proceeds) |
34M | 6.2M |
| Feb 27, 2024 |
10-K filing | 34.2M shares outstanding |
34M | 6.2M |
| Nov 09, 2023 |
10-Q filing | 30.6M shares outstanding |
31M | 6.2M |
| Nov 09, 2023 |
S-3 filing: The company intends to offer and sell up to $300 million in the aggregate of common stock, preferred stock, and debt securities from time to time. |
33M | 6.2M |
| Aug 10, 2023 |
10-Q filing | 32.6M shares outstanding |
33M | 0 |
| May 09, 2023 |
10-Q filing | 26.7M shares outstanding |
27M | 0 |
| Mar 17, 2023 |
10-K filing | 24.6M shares outstanding |
25M | 0 |
| Nov 09, 2022 |
10-Q filing | 26.7M shares outstanding |
27M | 0 |
| Aug 11, 2022 |
10-Q filing | 24.3M shares outstanding |
24M | 0 |
| May 11, 2022 |
10-Q filing | 20.7M shares outstanding |
21M | 0 |
| Mar 14, 2022 |
10-K filing | 20.6M shares outstanding |
21M | 0 |
| Nov 10, 2021 |
10-Q filing | 20.6M shares outstanding |
21M | 0 |
| Nov 01, 2021 |
S-3 filing: The company is filing an S-3 to offer and sell up to $300 million of common stock, preferred stock, and debt securities from time to time. |
21M | 0 |
| Aug 05, 2021 |
10-Q filing | 20.6M shares outstanding |
21M | 0 |
| May 11, 2021 |
10-Q filing | 20.3M shares outstanding |
20M | 0 |
| Mar 31, 2021 |
10-K filing | 20.5M shares outstanding |
21M | 0 |
| Nov 25, 2020 |
10-Q filing | 20.3M shares outstanding |
20M | 0 |
| Oct 09, 2020 |
S-1/A filing: This is an S-1/A filing for an offering of common stock. |
N/A | 0 |
| Sep 25, 2020 |
S-1 filing: This is an S-1 filing for an initial public offering of common stock by Tarsus Pharmaceuticals, Inc. |
N/A | 0 |